Report Identifies Nine Critical Payer Denial Trends
Sift Healthcare's fourth annual Denials Insights Report has identified nine payer trends shaping reimbursement risk for 2026. Key risks include an increase in pre-payment reviews, retroactive denials, and more aggressive medical necessity challenges. The report urges lab and pathology billing leaders to adopt predictive analytics for denial prevention rather than relying on reactive appeals.
Payers are escalating financial pressure on labs and pathology groups through increasingly sophisticated denial tactics. One of the most significant is the surge in DRG (Diagnosis-Related Group) downgrades, which increased by nearly 57% between 2022 and 2023. These downgrades, where payers retroactively challenge the diagnostic coding of inpatient stays, can slash reimbursement by thousands per case; a single sepsis case downgrade can result in a $5,316 payment cut. High-value, complex tests are a primary target. Molecular diagnostics face denial rates of over 35%, while routine anatomic pathology claims are denied about 20% of the time. Next-generation sequencing (NGS) for cancer has seen denial rates climb to 27.4%, with claims from independent labs being twice as likely to be denied as those from hospitals. The battleground has shifted from simple coding errors to clinical validation. Over 90% of DRG downgrades now arise from payers questioning the medical necessity of a diagnosis, not the code itself. This trend is particularly damaging for labs, as medical necessity documentation is now the most common failure point for molecular and pathology claims. Payers are leveraging AI and automated systems to enforce these stricter reviews, analyzing billing patterns to trigger audits and denials. This creates a significant operational burden, as the average cost to rework a single denied claim can be as high as $118, and up to 65% of denied claims are never resubmitted at all. Retroactive denials, or "clawbacks," represent another growing threat where payers reclaim payments months or even years after a claim has been settled. These automated recoupments create significant financial uncertainty and force billing teams to defend revenue that was previously considered secure. This environment makes a reactive, appeals-based approach to revenue cycle management unsustainable. The increasing complexity and cost of fighting denials mean labs that fail to adopt predictive, front-end prevention strategies face significant and ongoing revenue loss.
